Profile of darunavir in the management of treatment-experienced HIV patients
Cameron Wolfe, Charles HicksDuke University Medical Center, Division of Infectious Diseases, Durham, NC, USAAbstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-09-01
|
| Series: | HIV/AIDS: Research and Palliative Care |
| Online Access: | http://www.dovepress.com/profile-of-darunavir-in-the-management-of-treatment-experienced-hiv-pa-a3582 |
| _version_ | 1830339842968387584 |
|---|---|
| author | Cameron Wolfe Charles Hicks |
| author_facet | Cameron Wolfe Charles Hicks |
| author_sort | Cameron Wolfe |
| collection | DOAJ |
| description | Cameron Wolfe, Charles HicksDuke University Medical Center, Division of Infectious Diseases, Durham, NC, USAAbstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding to HIV protease. It has become an important drug, in combination with low-dose ritonavir boosting, in the treatment of both antiretroviral-naïve and multiclass-experienced patients. Growing data now exist suggesting it possesses a high barrier to resistance and requires multiple PI mutations in order to suffer reduced virological potency.Keywords: darunavir, HIV, ritonavir |
| first_indexed | 2024-12-19T21:04:34Z |
| format | Article |
| id | doaj.art-f8f886a94fd04aa68ae968125536033c |
| institution | Directory Open Access Journal |
| issn | 1179-1373 |
| language | English |
| last_indexed | 2024-12-19T21:04:34Z |
| publishDate | 2009-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | HIV/AIDS: Research and Palliative Care |
| spelling | doaj.art-f8f886a94fd04aa68ae968125536033c2022-12-21T20:05:42ZengDove Medical PressHIV/AIDS: Research and Palliative Care1179-13732009-09-012009Default1321Profile of darunavir in the management of treatment-experienced HIV patientsCameron WolfeCharles HicksCameron Wolfe, Charles HicksDuke University Medical Center, Division of Infectious Diseases, Durham, NC, USAAbstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding to HIV protease. It has become an important drug, in combination with low-dose ritonavir boosting, in the treatment of both antiretroviral-naïve and multiclass-experienced patients. Growing data now exist suggesting it possesses a high barrier to resistance and requires multiple PI mutations in order to suffer reduced virological potency.Keywords: darunavir, HIV, ritonavirhttp://www.dovepress.com/profile-of-darunavir-in-the-management-of-treatment-experienced-hiv-pa-a3582 |
| spellingShingle | Cameron Wolfe Charles Hicks Profile of darunavir in the management of treatment-experienced HIV patients HIV/AIDS: Research and Palliative Care |
| title | Profile of darunavir in the management of treatment-experienced HIV patients |
| title_full | Profile of darunavir in the management of treatment-experienced HIV patients |
| title_fullStr | Profile of darunavir in the management of treatment-experienced HIV patients |
| title_full_unstemmed | Profile of darunavir in the management of treatment-experienced HIV patients |
| title_short | Profile of darunavir in the management of treatment-experienced HIV patients |
| title_sort | profile of darunavir in the management of treatment experienced hiv patients |
| url | http://www.dovepress.com/profile-of-darunavir-in-the-management-of-treatment-experienced-hiv-pa-a3582 |
| work_keys_str_mv | AT cameronwolfe profileofdarunavirinthemanagementoftreatmentexperiencedhivpatients AT charleshicks profileofdarunavirinthemanagementoftreatmentexperiencedhivpatients |